BioSpace News Archive

PacBio, a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the international Consortium for Long-Read Sequencing, announced the launch of the first publicly available and free HiFi long-read variant frequency database with global representation.

Entos Pharmaceuticals (Entos or the Company), a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix PLV nucleic acid delivery platform, and its partner, Aegis Life, Inc. (Aegis), today announced that Entos has received approval from Health Canada to initiate a phase 1/2 clinical trial (NCT06436911) evaluating Covigenix VAX-002, an investigational COVID-19 booster vaccine.

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.

Longboard Pharmaceuticals, Inc. announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies.

Astellas is proud to announce that it is coordinating Patient Advocacy Organization Action Week™ — a community-driven collaboration comprised of more than 50 healthcare, patient advocacy and other organizations across the U.S.

Zynex, Inc. announced that it will participate in an analyst-led fireside chat on an RBC Capital Markets 2024 Medical Device Strategy & Innovation Call at 11:00 AM ET on Thursday, June 13, 2024.

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”), a leader in developing eco-friendly antimicrobial compounds, is pleased to announce significant advancements at its state-of-the-art bench scale production

GENFIT announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration accelerated approval of Iqirvo1 2 80 mg tablets – as unveiled today by Ipsen – as a first-in-class treatment for PBC in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.